Cronos (NASDAQ:CRNS)
Historical Stock Chart
From Jun 2019 to Jun 2024
![Click Here for more Cronos Charts. Click Here for more Cronos Charts.](/p.php?pid=staticchart&s=N%5ECRNS&p=8&t=15)
The Wynnefield Group, a long-term holder of 343,922 shares in the Cronos
Group (Nasdaq:CRNS), today urged other outside shareholders to make
their decision on how to vote in the proposed transaction based on a
review of the facts presented in the company’s
upcoming proxy filing.
On Wednesday, February 28, 2007, the Cronos Group –
one of the world's leading lessors of intermodal containers –
announced that it had entered into a definitive agreement to be
purchased by a group including certain members of the company’s
management team, as well as other third-party investors. Under the
agreement, the group will purchase all of Cronos' assets and assume all
of Cronos’ liabilities for a purchase price
equal to $16.00 per share.
Within 48 hours of the company’s February 28,
07 announcement, Alan Kahn, who to us seems like a “serial
plaintiff” in going private transactions
involving management, filed a lawsuit seeking substantial monetary
payment alleging among other things: conflict of interest; unfair terms;
breach of fiduciary duty; and flawed sales process. Mr. Kahn bases much
of his notion on the fact that the Cronos common share “had
recently traded as high as $18.24” and the
$16.00 bid therefore capped the Cronos share price. Wynnefield thinks
this is nonsense. What Mr. Kahn fails to mention is that the stock
traded at $18.24 only on one day (Jan 17, 2007). What he fails to
mention is that by Jan 24, 2007 the stock traded at $14.49. On Jan 31,
2007 it traded at $14.37, and on Feb 3, 2007 it traded at $14.30.
Informationally, the stock’s recent low was
$11.96 on Nov. 29, 2006. Further illustrating Mr. Kahn’s
“ready, fire, then aim”
approach, the lawsuit was commenced even before the company filed its
proxy statement which will provide detailed information about the sale
process, other elements of the transaction and the company’s
plan going forward.
Nelson Obus, Managing Partner of Wynnefield commented, “It
is unfortunate that an individual who claimed for many years to be a
value investor, comports himself in this way. Wynnefield, like other
value oriented funds, invests on the basis that stocks of particular
companies are mispriced by the market. Value research is directed to
understanding what the market has not understood about a particular
situation and investing accordingly.” Mr.
Obus went on to say, “Alan Kahn certainly
knows that stocks are infrequently fairly valued, and to now allege that
a single day when the stock achieved its highest price in recent history
should be the benchmark from which a ‘premium’
should then be offered is embarrassing to the value investing community.
However, since Alan did not even wait to see what was in the proxy
before filing his lawsuit, one can only speculate on his underlying
motivation. What we know for sure is that this motivation is not based
on the complete facts, since he will not even have them until the proxy
is filed.”
“As a long-time significant shareholder in
this company, we urge all outside shareholders to determine how to vote
on the proposed transaction based on the facts. And those facts will be
presented in the company’s upcoming proxy
filing – not in the latest baseless lawsuit
from Alan Kahn,” concluded Obus.
ABOUT THE WYNNEFIELD GROUP:
The Wynnefield Group includes several affiliates of Wynnefield Capital,
Inc. (WCI), a value investor specializing in U.S. small cap situations
that have company- or industry-specific catalysts. WCI was established
in 1992. Its founding partners, Nelson Obus and Joshua Landes, held
senior research and institutional equity positions at Lazard Freres &
Co. during the 1980s, and the initial Wynnefield investors included many
of their colleagues at Lazard. The fund has grown to approximately $400
million under management. Nelson Obus currently serves on the board of
directors of Layne Christensen Company (NASDAQ: LAYN), serving on its
audit committee and compensation committee.